Janus kinase (JAK) inhibitor medications are designed to block an overactive pathway of enzymes. They limit the production of immune messengers called cytokines that cause eczema symptoms. This reduces inflammation, skin thickness and scaling, relieves itching and promotes clear skin.
These medications work quickly to ease itching, inflammation, and other symptoms. If you’ve had trouble controlling your condition with other prescription drugs, JAK inhibitors might work for you.
Several JAK inhibitors have been approved for the treatment of atopic dermatitis, incluing
- Abrocitinib (Cibinqo®). This is an oral medication taken by mouth and prescribed to adults with refractory, moderate to serious atopic dermatitis
- Ruxolitinib (Opzelura®). This is a topical medicine applied to the skin
- Upadacitinib (Rinvoq). This is an oral medication taken by mouth and prescribed to adults and children over age 12 with moderate to serious atopic dermatitis
Baricitinib is another JAK inhibitor awaiting FDA review.
JAK inhibitors are approved for adults and children ages 12 and older with moderate to severe atopic dermatitis.
Medication side effects may include mild nausea, nasal swelling, cough, headaches and high blood pressure.
JAK inhibitors alter the immune system’s ability to react to germs, which can put patients at risk for bacterial, fungal and viral infections and/or certain cancers.
FDA requires product warnings on JAK inhibitors about increased risk of serious heart-related events and blood clots.
JAK inhibitors are expensive, but they are usually covered by insurance.
© 2021 Allergy and Asthma Network
Last updated : 7/3/2024